Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- 2.6k Downloads
The clinical efficacy of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been demonstrated in ALK fusion-positive non-small cell lung cancer (NSCLC); however, brain metastases are frequent sites of initial failure in patients due to poor penetration of the central nervous system by crizotinib. Here, we examined the efficacy of a selective ALK inhibitor alectinib/CH5424802 in preclinical models of intracranial tumors.
We established intracranial tumor implantation mouse models of EML4–ALK-positive NSCLC NCI-H2228 and examined the antitumor activity of alectinib in this model. Plasma distribution and brain distribution of alectinib were examined by quantitative whole-body autoradiography administrating a single oral dose of 14C-labeled alectinib to rats. The drug permeability of alectinib was evaluated in Caco-2 cell.
Alectinib resulted in regression of NCI-H2228 tumor in mouse brain and provided a survival benefit. In a pharmacokinetic study using rats, alectinib showed a high brain-to-plasma ratio, and in an in vitro drug permeability study using Caco-2 cells, alectinib was not transported by P-glycoprotein efflux transporter that is a key factor in blood–brain barrier penetration.
We established intracranial tumor implantation models of EML4–ALK-positive NSCLC. Alectinib showed potent efficacy against intracranial EML4–ALK-positive tumor. These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with brain metastases.
KeywordsNSCLC ALK ALK inhibitor Brain metastases Alectinib
We thank T. Mizuno for the establishment of luciferase-expressing cells; A. Nakagawa and F. Sawamura for the in vivo experiments; and T. Shiga and K. Honda for the tissue-staining experiments.
Conflict of interest
All of the authors are employees of Chugai Pharmaceutical Co., Ltd.
- 6.Weickhardt AJ, Scheier B, Burke JM et al (2012) Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK + non-small cell lung cancer (NSCLC). J Clin Oncol 30:suppl; abstr 7526Google Scholar
- 9.Kuromitsu S, Mori M, Shimada I et al (2011) Anti-tumor activity of ASP3026, —a novel and selective ALK inhibitor. Cancer Res 71:suppl; abstract 2821Google Scholar
- 12.US FDA. (2012) Guidance for industry. Drug interaction studies—study design, data analysis, and implications for dosing and labeling recommendations, Rockville, USAGoogle Scholar
- 13.Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H (2014) Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351:215–221Google Scholar
- 14.Tan W, Wilner KD, Bang Yet al (2010) Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol 28:suppl; abstr 2596Google Scholar
- 15.Pfizer Inc. XALKORI® (crizotinib) Capsules, oral. Prescribing information. New York, USA, 2011; Revised May 2013Google Scholar
- 17.Fushiki H, Saito R, Jitsuoka M et al (2013) First demonstration of in vivo PET imaging for ALK inhibitor using [11C]ASP3026, a novel brain-permeable type of ALK inhibitor. Cancer Res 73:suppl; abstr 2678Google Scholar
- 25.Ou SH, Gadgeel S, Chiappori A et al (2013) Safety and efficacy analysis of alectinib (CH5424802/RO5424802) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose finding phase I study (AF-002JG, NCT01588028). Ann Oncol:44 LBAGoogle Scholar